PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
May 20, 2026American Journal of Respiratory and Critical Care Medicine0 citations

Pulmonary Delivery of Antisense Oligonucleotide and Feldan Shuttle Decrease Mucin Gene Expression

C70-05 Pulmonary Administration of Antisense Oligonucleotide (ASO) and Feldan Shuttle Delivery Peptide Decreases Mucin Gene Expression in Models of Muco-obstructive Lung Diseases

View Full Paper
Ask AI
Bookmark
Share

Authors

ACA ChengMPM PelletierMHM Hervault

Discussion

Loading...

Member takes

Overview

Randomized trial demonstrates reduced mucin gene expression in muco-obstructive lung disease models, indicating therapeutic potential.

Key Points

  • This research aims to explore the effectiveness of antisense oligonucleotides delivered via the Feldan Shuttle to inhibit mucin gene expression in airway diseases.
  • Developed a therapeutic strategy utilizing a peptide delivery system and antisense oligonucleotides targeting mucin genes.
  • Evaluated treatment effects in disease-related models, including primary human bronchial epithelial cells and a mouse model of mucus hypersecretion.
  • Achieved approximately 85% gene knockdown in human bronchial epithelial cells by RT-qPCR.
  • Demonstrated an approximate 90% reduction of mucin mRNA in lung extracts in a mouse model, with significant decreases in inflammatory cytokines.

Cite This Study

Cheng et al. (2026) studied this question.

synapsesocial.com/papers/6a0d5098f03e14405aa9c7e7https://doi.org/10.1093/ajrccm/aamag162.5421
View Full Paper
Ask AI
Bookmark
Share